GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Gennex Laboratories Ltd

Gennex Laboratories Q2 FY27 Standalone Net Profit at Rs. 335.15 lakhs

RESULTS ▼ Concern Flagged MEDIUM RISK
📅 Filed on BSE: 14 Nov 2026, 06:27 PM IST  ·  BSE ID: 0e286237-e96c-48d1-913c-b81094205c72
View Original BSE Filing (PDF)
💡
In Simple Terms
Gennex Laboratories reported its financial results for the latest quarter and half-year, showing its profit and revenue.
🤖 AI Summary
  • Standalone Net Profit for Q2 FY27 was Rs. 335.15 lakhs, compared to Rs. 453.32 lakhs in Q2 FY26.
  • Standalone Revenue from Operations for Q2 FY27 reached Rs. 3,076.26 lakhs.
  • Half-year ended September 30, 2026, standalone net profit totaled Rs. 730.68 lakhs.
  • Total standalone assets stood at Rs. 29,433.58 lakhs as of September 30, 2026.
  • Board approved reconstitution of Audit, Nomination & Remuneration, and Stakeholders Relationship Committees.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Standalone Revenue from Operations (Q2 FY27)
3,076.26 Rs.lakhs
5.03
Standalone Net Profit (Q2 FY27)
335.15 Rs.lakhs
-26.08
Standalone Basic EPS (Q2 FY27)
0.138 Rs.
-26.37
Consolidated Revenue from Operations (Q2 FY27)
4,226.47 Rs.lakhs
13.48
Consolidated Net Profit (Q2 FY27)
443.37 Rs.lakhs
-18.57
Standalone Total Assets (Sep 30, 2026)
29,433.58 Rs.lakhs
7.49
🏢 How This Affects the Company
📈
Business Impact
The company's core 'Bulk Drugs' manufacturing segment, which includes products like Guaifenesin and Methocarbamol, contributed to a standalone revenue of Rs. 3,076.26 lakhs for Q2 FY27.
💰
Financial Impact
Standalone Net Profit for Q2 FY27 decreased to Rs. 335.15 lakhs from Rs. 453.32 lakhs in Q2 FY26, impacting quarterly earnings. Half-year standalone net profit increased to Rs. 730.68 lakhs from Rs. 868.27 lakhs in the prior comparable period.
⚙️
Operational Impact
The dissolution of the Rights Issue Committee indicates the conclusion of specific capital raising activities, shifting focus to other operational aspects.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, as reflected in the Q2 FY27 standalone basic EPS of Rs. 0.138, down from Rs. 0.187 in Q2 FY26.
🔍
Management Signal
The Board's approval of the financial results and reconstitution of key committees signals a focus on statutory compliance and corporate governance.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — review revenue and profit trends.
Updates on operational efficiencies or cost management initiatives.
Any further announcements regarding committee compositions or responsibilities.
MEDIUM RISK Quarterly standalone net profit and EPS have declined year-on-year, indicating potential short-term earnings pressure.
💡 Investor Takeaway
Gennex Laboratories reported Q2 FY27 standalone net profit of Rs. 335.15 lakhs, a 26.08% decline from Rs. 453.32 lakhs in Q2 FY26. Half-year standalone net profit was Rs. 730.68 lakhs, with revenue from operations at Rs. 6,544.05 lakhs. Consolidated half-year revenue reached Rs. 8,210.64 lakhs.
⚖️ Strengths & Concerns

✅ Positives

  • Half-year ended September 30, 2026, standalone total income from operations increased to Rs. 6,919.36 lakhs from Rs. 5,927.25 lakhs YoY.
  • Consolidated Revenue from Operations for the half-year ended September 30, 2026, rose to Rs. 8,210.64 lakhs from Rs. 7,141.96 lakhs YoY.

⚠️ Concerns

  • Standalone Net Profit for Q2 FY27 decreased to Rs. 335.15 lakhs from Rs. 453.32 lakhs in Q2 FY26, a 26.08% reduction.
  • Standalone Basic Earnings Per Equity Share (EPS) for Q2 FY27 declined to Rs. 0.138 from Rs. 0.187 in Q2 FY26, a 26.37% decrease.
📅 Company Track Record
Gennex Laboratories had informed BSE on July 29, 2026, about a Board Meeting to be held on August 14, 2026, for Q1 FY27 financial results. This current filing details the Q2 FY27 results and half-year performance.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Gennex Laboratories' standalone net profit for Q2 FY27?
Gennex Laboratories reported a standalone net profit of Rs. 335.15 lakhs for the quarter ended September 30, 2026 (Q2 FY27), which is a 26.08% decrease from Rs. 453.32 lakhs in Q2 FY26.
What was the standalone revenue from operations for Gennex Laboratories in Q2 FY27?
The standalone revenue from operations for Gennex Laboratories for the quarter ended September 30, 2026, was Rs. 3,076.26 lakhs.
What was the consolidated revenue from operations for Gennex Laboratories for the half-year ended September 30, 2026?
The consolidated revenue from operations for Gennex Laboratories for the half-year ended September 30, 2026, was Rs. 8,210.64 lakhs, an increase from Rs. 7,141.96 lakhs in the prior comparable period.
What were Gennex Laboratories' total standalone assets as of September 30, 2026?
As of September 30, 2026, Gennex Laboratories' total standalone assets amounted to Rs. 29,433.58 lakhs, compared to Rs. 27,382.13 lakhs as of March 31, 2026.
Which committees of Gennex Laboratories were reconstituted by the Board?
The Board of Directors approved the reconstitution of the Audit Committee, Nomination & Remuneration Committee, and Stakeholders Relationship Committee.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.

Live IPO, GMP and market updates on Telegram

IPO open and close dates, grey market premium moves, subscription figures, allotment and listing days, and the market updates worth knowing about, posted on the channel as they happen.

Join the channel